GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phio Pharmaceuticals Corp (NAS:PHIO) » Definitions » E10

PHIO (Phio Pharmaceuticals) E10 : $-43,242.80 (As of Sep. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Phio Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Phio Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2024 was $-1.540. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-43,242.80 for the trailing ten years ended in Sep. 2024.

During the past 3 years, the average E10 Growth Rate was 51.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Phio Pharmaceuticals was 51.10% per year. The lowest was 51.10% per year. And the median was 51.10% per year.

As of today (2024-12-15), Phio Pharmaceuticals's current stock price is $2.81. Phio Pharmaceuticals's E10 for the quarter that ended in Sep. 2024 was $-43,242.80. Phio Pharmaceuticals's Shiller PE Ratio of today is .


Phio Pharmaceuticals E10 Historical Data

The historical data trend for Phio Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phio Pharmaceuticals E10 Chart

Phio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -795,756.00 -670,937.00 -294,779.00 -93,172.70

Phio Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -119,382.00 -93,172.70 -70,602.80 -54,047.10 -43,242.80

Competitive Comparison of Phio Pharmaceuticals's E10

For the Biotechnology subindustry, Phio Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phio Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Phio Pharmaceuticals's Shiller PE Ratio falls into.



Phio Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Phio Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-1.54/133.0289*133.0289
=-1.540

Current CPI (Sep. 2024) = 133.0289.

Phio Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201412 -74,756.800 99.070 -100,382.002
201503 -60,192.300 99.621 -80,377.706
201506 -20,091.700 100.684 -26,546.218
201509 -22,899.100 100.392 -30,343.626
201512 -23,781.800 99.792 -31,702.481
201603 -20,281.800 100.470 -26,854.333
201606 -20,109.100 101.688 -26,306.829
201609 -19,927.900 101.861 -26,025.531
201612 -20,247.700 101.863 -26,442.744
201703 -14,717.000 102.862 -19,033.098
201706 -6,429.670 103.349 -8,276.143
201709 -6,221.110 104.136 -7,947.209
201712 -4,894.870 104.011 -6,260.478
201803 -4,931.720 105.290 -6,231.023
201806 -2,589.920 106.317 -3,240.637
201809 -1,993.320 106.507 -2,489.695
201812 -593.994 105.998 -745.471
201903 -616.680 107.251 -764.903
201906 -498.960 108.070 -614.198
201909 -489.240 108.329 -600.789
201912 -507.021 108.420 -622.103
202003 -143.640 108.902 -175.464
202006 -36.720 108.767 -44.911
202009 -43.200 109.815 -52.332
202012 -44.280 109.897 -53.600
202103 -34.560 111.754 -41.139
202106 -21.600 114.631 -25.067
202109 -30.240 115.734 -34.759
202112 -27.585 117.630 -31.196
202203 -21.060 121.301 -23.096
202206 -19.980 125.017 -21.260
202209 -28.260 125.227 -30.021
202212 -21.600 125.222 -22.947
202303 -28.350 127.348 -29.615
202306 -13.270 128.729 -13.713
202309 -10.250 129.860 -10.500
202312 -1.520 129.419 -1.562
202403 -4.230 131.776 -4.270
202406 -3.620 132.554 -3.633
202409 -1.540 133.029 -1.540

Add all the adjusted EPS together and divide 10 will get our e10.


Phio Pharmaceuticals  (NAS:PHIO) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Phio Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Phio Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Phio Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
11 Apex Drive, Suite 300A PMB 2006, Marlborough, MA, USA, 01752
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Executives
Robert J Bitterman director C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581
Robert L Ferrara director 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Patricia A Bradford director UNISYS CORPORATION, 801 LAKEVIEW DRIVE, SUITE 100, BLUE BELL PA 19422
Gerrit Dispersyn officer: Chief Development Officer 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
John A Barrett officer: Chief Development Officer 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Geert Cauwenbergh director, officer: President and CEO 1 STULTS DRIVE, PLAINSBORO NJ 08536
Alexey Eliseev officer: Chief Business Officer 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Jonathan E Freeman director 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Curtis Lockshin director 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
H. Paul Dorman director 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581
Opko Health, Inc. 10 percent owner 4400 BISCAYNE BLVD., MIAMI FL 33137
Advanced Rna Technologies, Llc 10 percent owner 1 KENDALL SQUARE BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Keith L Brownlie director 777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Pamela Pavco officer: Chief Development Officer C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, WESTBOROUGH MA 01581
Caitlin Kontulis officer: Secretary and Controller 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581